Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18128266 | 1.00 | PARP1 (0.56) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL31402329 | 0.85 | CREBBP (0.60) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL5672928 | 0.85 | CREBBP (0.60) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL3635930 | 0.80 | PARP1 (0.56) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL2070598 | 0.80 | PARP1 (0.56) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL12540763 | 0.80 | PARP1 (0.56) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL12540759 | 0.80 | PARP1 (0.56) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL3593519 | 0.80 | PARP1 (0.56) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL20983200 | 0.80 | PARP1 (0.56) | PARP1BRD4DRD2CREBBPTRPV1 | |
| SCHEMBL18128142 | 0.80 | PARP1 (0.47) | PARP1BRD4DRD2TRPV1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080115-B1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-05-08 | — | — | EP | disclosed |
| US-9868749-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-16 | — | — | US | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | PARP1 1485/4885BRD4 811/4885DRD2 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.